Announced Date: 2025-12-15 (December 15, 2025)
Licensor (Seller): Innolake Biopharm (Innolake, 因诺湖) (China)
Licensee (Buyer): Ellipses Pharma (UK)
.
Asset Name: ILB-3101 (EP0028)
Asset Modality: ADC; Asset Target: B7H3
Potential Indication: Graves’ Disease and Thyroid Eye Disease
Current Stage:
.
Scope of Authority:
Agreement grants Yarrow Bioscience, Inc. exclusive global ex-China rights to develop and commercialize GS-098 (YB-101) for Graves’ disease (GD) and thyroid eye disease (TED).
.
Payment Detail: Undisclosed.
.
Link:
.
Note:
